Truist analyst Nicole Germino downgraded Fusion Pharmaceuticals (FUSN) to Hold from Buy with a price target of $21, up from $11. Given the firm’s expectation that the company’s just-announced deal with AstraZeneca (AZN) is likely to close without issue, it thinks Fusion’s stock is no longer trading on fundamentals and will stay close to, if not at, the proposed deal price, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FUSN:
- UK Stocks: AstraZeneca (AZN) Expands Cancer Portfolio with Fusion Pharma Acquisition
- Fusion Pharmaceuticals’ Acquisition and Future Focus Shift
- Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
- Fusion Pharmaceuticals Inc (FUSN) Q4 Earnings Cheat Sheet
- 3 Best Stocks to Buy Now, 3/5/2024, According to Top Analysts
